Dhriti Shivlani

Oct 8, 2024 | consumernotice.org | Bianca Prieto |Dhriti Shivlani |Emily Miller

The Environmental Protection Agency is proposing greater public access to data on over 100 toxic Per- and Polyfluoroalkyl Substances (PFAS), also called “forever chemicals.”The information will be added to the Toxics Release Inventory (TRI), aiming to increase transparency and public awareness. It will also address growing concerns about the environmental and health issues linked to these dangerous man-made chemicals.

Aug 8, 2024 | consumernotice.org | Emily Miller |Dhriti Shivlani

Following a decade of orders, studies and warnings, the Environmental Protection Agency has issued an emergency order to cease all usage of the weed killer Dacthal, also known as DCPA. The emergency order took immediate effect on Tuesday and all of the pesticide’s registrations have been suspended. This marks the first time in nearly 40 years that the EPA has issued an emergency suspension of this nature.

Jul 29, 2024 | consumernotice.org | Terry Turner |Dhriti Shivlani

A St. Louis jury has ordered Abbott Laboratories to pay $495 million in damages to a family who claimed the company’s baby formula caused necrotizing enterocolitis (NEC). The verdict issued on Friday is one of the first significant outcomes in a series of high-profile cases involving premature infant formulas and their alleged links to serious health complications.

Jul 16, 2024 | consumernotice.org | Bianca Prieto |Dhriti Shivlani

Lawyers in the Bard PowerPort MDL have chosen 24 lawsuits to undergo a fact-finding process in preparation for potential bellwether trials. These trials aim to gauge jury response to evidence and shape settlements for the over 320 similar cases consolidated in federal court. Bellwether trials involve a small group of cases selected for early trials. They offer valuable insights into how juries might respond to the broader litigation.

Jul 10, 2024 | consumernotice.org | Michelle Llamas |Dhriti Shivlani

Semaglutide-containing drugs such as Ozempic, Wegovy and Rybelsus may have an association with an increased risk of a sight-threatening eye condition, a new study suggests. The study published in JAMA Ophthalmology included 16,827 patients for analysis and gathered a sample size of 629 cases of nonarteritic anterior ischemic optic neuropathy (NAION).